The 21 most recent market catalysts affecting $HAE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 65
Haemonetics Announces CE Mark Certification for the VASCADE MVP XL Venous Vascular Closure System
Haemonetics announced it received CE Mark certification for its VASCADE MVP XL venous vascular closure system. This approval is significant as it allows Haemonetics to market and d…
Nov 13, 2026
Corporate Catalyst
Neutral
Impact 65
Jefferies Initiates Coverage on Haemonetics With Buy Rating
Jefferies has initiated research coverage on Haemonetics Corporation, assigning a 'Buy' rating and a $150 price target. This event is significant as new analyst coverage, especiall…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 65
Citigroup and Barrington Research Update Analyst Ratings for Haemonetics
Citigroup maintained its Buy rating on Haemonetics and raised its price target from $123 to $149, while Barrington Research maintained its Outperform rating and increased its price…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Barrington Research Adjusts Haemonetics Price Target to $145
Barrington Research's decision to raise Haemonetics' price target to $145 from $140, alongside maintaining an Outperform rating, is a direct response to the company's robust fiscal…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results
This 8-K filing from Haemonetics Corporation serves as a notification that the company has released its financial results for the second quarter of fiscal year 2027. The filing its…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Haemonetics received FDA approval for its PerQseal Elite vascular closure system, a significant regulatory milestone that allows the company to commercialize this device in the U.S…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 55
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintained an 'Outperform' rating on Haemonetics (HAE) and raised the price target from $118 to $140. This action indicates a more bulli…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Haemonetics (HAE) and substantially raised the price target from $95 to $140. This action signals increased conf…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $110 to $130.
This headline represents a strong positive corporate catalyst for Haemonetics. The maintained 'Buy' rating signals continued confidence, while the substantial price target increase…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130
BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics (HAE) and raised the price target from $110 to $130. This action signals increased confidence from the analyst …
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 85
Haemonetics Stock Hits 52-Week High - Here's Why
Haemonetics disclosed that CSL Plasma, a major customer, intends to fully integrate Haemonetics' NexSys PCS devices and related disposables across all its U.S. plasma collection ce…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123
Citigroup analyst Joanne Wuensch upgraded Haemonetics (HAE) from a 'Neutral' to a 'Buy' rating and significantly raised the price target from $92 to $123. This upgrade indicates a …
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 65
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125
Raymond James analyst Andrew Cooper has updated their outlook on Haemonetics, maintaining an 'Outperform' rating and raising the price target from $105 to $125. This indicates a st…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Haemonetics, Raises Price Target to $119
Baird analyst David Rescott maintained an 'Outperform' rating on Haemonetics (HAE) and significantly raised the price target from $96 to $119. This action signals increased confide…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 60
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $118
Barrington Research, through analyst Michael Petusky, has maintained an 'Outperform' rating on Haemonetics (HAE) and raised its price target from $95 to $118. This action signals i…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics Shares Hit New 52-Week High: What's Happening?
Haemonetics (HAE) announced a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL to adopt Haemonetics’ NexSys PCS devices and Persona PLUS technology across its U.S.…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Haemonetics, Raises Price Target to $110
BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics and raised the price target from $96 to $110. This action signals increased analyst optimism regarding Haemonet…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics shares are trading higher after the company announced it entered into a supply agreement with CSL Plasma.
This supply agreement is a significant positive catalyst for Haemonetics, as it secures a major customer and likely expands its market share in the plasma collection equipment sect…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Haemonetics, Raises Price Target to $96
BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics and raised the price target from $84 to $96. This action signals a positive outlook from a reputable financial …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate
This headline is a significant corporate catalyst for Haemonetics (HAE). Beating both EPS and sales estimates by a notable margin indicates strong underlying business fundamentals,…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90
Mizuho analyst Anthony Petrone has maintained an 'Outperform' rating on Haemonetics (HAE) and raised the price target from $85 to $90. This action signals continued confidence from…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.